" Sorry , I cannot answer any questions as I have not been in the job long enough " .
Azar is a poster boy for Washingtonâs revolving door. Itâs a wonder vertigo doesnât prevent him from remaining upright.
The best one can say is that he at least has some actual government experience, but in the end, heâs just another Trump toady.
His photo makes him look like the poster child of The Society for Reckless Self-MedicationâŚ
In prepared remarks released Tuesday night, Azar said âdrug prices are too high,â placing the issue as his top priority. He shied away from detailed proposals, however, saying instead that he has the knowledge and experience to get drug companies, pharmacies, insurers and government programs to work toward solutions.
His knowledge and experience should suggest that if you leave it up to the companies to work out solutions, if you donât explicitly tell them what they have to do, the consumer is not likely to come out paying less.
Why would TPM reprint this silly article? Tom Daschle? Cripes, the poster boy for the linkedin neoliberal swamp that is the Democratic party. I mean how did he get into this? Yes, Azar is âfriendsâ with everybody who is anybody in the Beltway. Meaning anyone whose net worth is over several million dollars.
I hate to have to say this, but sorry Josh, your never going to come close to that number.
If the likes of Betsy DeVos and Jeff Sessions got confirmed, this putz is a shoe-in. There is no GOP clown too unqualified to be denied a cushy sinecure at the feet of The Orange ShitgibbonâŚ
The only thing in the Trump election agenda that I thought was a good idea has now been dropped. And, of course, he is taking on the industry mantra that the problem is all those foreigners with universal health care systems that negotiate prices are the cause of why they have to extort so much money out of USA drug consumers.
The theme of the presidentâs initiative is âAmerican patients first,â and his plan takes aim at what the White House calls âforeign freeloading.â The administration will, as expected, put pressure on foreign countries to relax drug price controls, in the belief that pharmaceutical companies can then lower prices in the United States.